Loading…
Bolt Biotherapeutics, Inc. is projected to rise to $3.81 by 2027, a +1% move from its current price of $3.78. BOLT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $3.66 | $3.78 | $3.91 | +0.03% |
| Jul 15 | $3.61 | $3.78 | $3.96 | +0.05% |
| Jul 16 | $3.57 | $3.78 | $4.00 | +0.08% |
| Jul 17 | $3.54 | $3.78 | $4.04 | +0.10% |
| Jul 18 | $3.52 | $3.78 | $4.07 | +0.13% |
| Jul 19 | $3.49 | $3.79 | $4.10 | +0.15% |
| Jul 20 | $3.47 | $3.79 | $4.13 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.47 | $3.79 | $4.13 | +0.18% |
| Week 2 | $3.35 | $3.79 | $4.29 | +0.36% |
| Week 3 | $3.27 | $3.80 | $4.42 | +0.54% |
| Week 4 | $3.20 | $3.81 | $4.53 | +0.72% |
| Week 5 | $3.14 | $3.81 | $4.63 | +0.90% |
| Week 6 | $3.09 | $3.82 | $4.73 | +1.09% |
| Week 7 | $3.04 | $3.83 | $4.82 | +1.27% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel immunotherapies for the treatment of cancer. The company’s pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc.
in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Bolt Biotherapeutics, Inc. trades under the symbol BOLT. The current price is $3.91 and the market capitalization is $7.5M, with a rank of 4917. The stock is positioned in the healthcare sector as a clinical-stage biopharmaceutical company with a development focus on immunotherapies for cancer.
The current price and market position sit within a broader forecast that envisions a multi-year path from modest levels toward higher price points, driven by varying yearly expectations. The latest price snapshot shows a near-term context that blends uncertainty with potential upside per year-by-year forecasts.
A major floor 27.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 40.5% above — a clean break opens room to run.
A major ceiling 54.0% above — clearing it would confirm fresh momentum.
Key BOLT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BOLT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.97 | Sell | $3.94 | Sell |
| MA 10 | $3.99 | Sell | $4.01 | Sell |
| MA 20 | $4.15 | Sell | $4.16 | Sell |
| MA 50 | $4.55 | Sell | $4.43 | Sell |
| MA 100 | $4.59 | Sell | $4.67 | Sell |
| MA 200 | $5.06 | Sell | $5.24 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.88 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -122.70 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -11.37 | Sell |
| Bollinger %B (20,2) | 0.13 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.63 | Sell |
| Awesome (5,34) | -0.49 | Sell |
| Ultimate (7,14,28) | 41.64 | Neutral |
| Momentum (10) | -0.42 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 3.95 | Sell |
| ADX (14) | 17.14 | Neutral |
| ATR (14) | 0.13 | Info |
The near-term technical picture is bearish, with RSI(14) at 40. The market is trading below the 50-day and 200-day moving averages, which stand at $4.71 and $5.12 respectively. Immediate support is at $3.90 and resistance at $5.31.
The 30-day price range runs from a low of $3.03 to a high of $5.04, highlighting a notable swing range in the near term. Annualized volatility is high at 70%, underscoring substantial price movement potential over the coming weeks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.78 | $3.78 | $5.04 | 0% | Neutral | |
| $2.98 | $3.81 | $5.19 | +1% | Neutral | |
| $2.98 | $3.94 | $5.61 | +4% | Neutral | |
| $3.84 | $5.24 | $7.71 | +39% | Bullish | |
| $3.84 | $5.36 | $8.12 | +42% | Bullish | |
| $3.78 | $5.40 | $8.39 | +43% | Bullish | |
| $3.78 | $5.53 | $8.78 | +46% | Bullish | |
| $3.32 | $4.95 | $8.01 | +31% | Bullish | |
| $3.81 | $5.80 | $9.55 | +53% | Bullish | |
| $4.65 | $7.22 | $12.09 | +91% | Bullish | |
| $4.66 | $7.88 | $14.17 | +109% | Bullish | |
| $8.52 | $16.77 | $33.35 | +344% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.78 | $3.78 | $4.49 | +0.00% |
| August 2026 | $3.25 | $3.86 | $4.72 | +2.12% |
| September 2026 | $3.23 | $3.87 | $4.79 | +0.25% |
| October 2026 | $3.11 | $3.75 | $4.69 | -3.21% |
| November 2026 | $3.14 | $3.81 | $4.82 | +1.70% |
| December 2026 | $3.24 | $3.96 | $5.04 | +3.87% |
Click any year to see its month-by-month BOLT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The BOLT price prediction for 2026 points to an average of $3.78 (low $3.78, high $5.04) — a potential gain of 0% on today's $3.78. Price action looks broadly range-bound.
In 2027, BOLT is projected to trade between $2.98 and $5.19, averaging $3.81 — a potential gain of +1% from today's $3.78. That is up +1% on the projected 2026 average. A consolidation phase looks the most probable path here.
Bolt Biotherapeutics, Inc.'s 2028 outlook centres on $3.94, within a $2.98 to $5.61 range. That is up +4% on the projected 2027 average. That marks a +4% change versus current levels. Price action looks broadly range-bound.
By 2029, BOLT could reach as high as $7.71, with a base case around $5.24 and support toward $3.84 — roughly +39% from $3.78. Buyers look set to stay in control over this stretch.
Expect BOLT to range from $3.84 to $8.12 through 2030. The $5.36 average target implies a +42% move from current prices. That is up +2% on the projected 2029 average. Momentum favours further upside here.
The BOLT price prediction for 2031 points to an average of $5.40 (low $3.78, high $8.39) — a potential gain of +43% on today's $3.78. Buyers look set to stay in control over this stretch.
In 2032, BOLT is projected to trade between $3.78 and $8.78, averaging $5.53 — a potential gain of +46% from today's $3.78. That is up +2% on the projected 2031 average. Momentum favours further upside here.
Bolt Biotherapeutics, Inc.'s 2033 outlook centres on $4.95, within a $3.32 to $8.01 range. That is -11% versus the projected 2032 average. That marks a +31% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, BOLT could reach as high as $9.55, with a base case around $5.80 and support toward $3.81 — roughly +53% from $3.78. Momentum favours further upside here.
Expect BOLT to range from $4.65 to $12.09 through 2035. The $7.22 average target implies a +91% move from current prices. That is up +24% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The BOLT price prediction for 2040 points to an average of $7.88 (low $4.66, high $14.17) — a potential gain of +109% on today's $3.78. Momentum favours further upside here.
In 2050, BOLT is projected to trade between $8.52 and $33.35, averaging $16.77 — a potential gain of +344% from today's $3.78. That is up +113% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in BOLT today (≈ 264.550265 BOLT) could be worth
$4,437.29
+$3,437.29 (+344%) by 2050 · US Dollar
Based on the average projected BOLT price of $16.77 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BOLTwould be worth at today's price.
$1,000 invested in BOLT on Jul 10, 2025 (≈ 158.227844 BOLT) would be worth
$598.1
-$401.9 (-40.2%) today · 0.60× · US Dollar
Based on a BOLT entry price of $6.32 vs. today's $3.78.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.05 | $933.33 | -6.7% |
| 1 month ago | $4.43 | $853.27 | -14.7% |
| 3 months ago | $4.91 | $769.86 | -23.0% |
| 6 months ago | $5.81 | $650.6 | -34.9% |
| 1 year ago | $6.32 | $598.1 | -40.2% |
| All time (5.0y) ago | $260.4 | $14.52 | -98.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BOLT forecast.
Our base-case forecast reaches $7.60 around 2040.
Implied market cap at $7.60: $14.6M
The multi-year forecast shows a gradual rise in the average price and a steady improvement in upside potential. The 2029 forecast lists an average price of $5.58 with a 42.8% ROI and a bullish sentiment. The 2030 forecast increases to an average of $5.62 with a 44% ROI and a bullish tone, followed by continued gains through 2032 (avg $5.71, ROI 46.3%).
In 2034 the average price reaches $6.12 with a 56.7% ROI and a bullish outlook, and 2035 shows an average of $7.66 with a 96.2% ROI. The long horizon strengthens further: 2040 has an average of $8.24 with an 111% ROI and a bullish stance, while 2050 projects an average of $17.55 with a 349.4% ROI. The forecast also notes a dip in 2027 with a -2% ROI, illustrating that the path is not linear.
Overall, the long-term picture points to a bullish trajectory into the 2030s and beyond, but these are estimates and not guarantees. Investors should consider the mix of positive and negative-year signals across the forecast horizon.
Tap a question to reveal the answer.
The 2030 forecast lists min $3.86, avg $5.62, max $8.88 with ROI 44% and sentiment BULLISH.
Yes. The forecast shows a 2034 max of $10.61 and a 2035 max of $13.55, with a bullish sentiment.
The forecast includes multiple years with positive ROI (e.g., 2029 42.8%, 2030 44%, 2031 45.7%, 2032 46.3%, 2034 56.7%, 2035 96.2%, 2040 111%, 2050 349.4%), though 2027 shows a -2% ROI. These are estimates, not guarantees.
The near-term view is bearish (sentiment BEARISH) with RSI(14) at 40. The price is near support at $3.90 and resistance at $5.31, within a 30-day range of $3.03 to $5.04.
Current price is $3.91 and market cap is $7.5M.
Bolt Biotherapeutics, Inc. Community Discussion
0Share your Bolt Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.